- YD Bio Limited successfully completed its business combination with Breeze Holdings Acquisition Corp. and began trading its common stock and warrants on the Nasdaq Global Market under the ticker symbols **"YDES"** and **"YDESW"** on **August 29, 2025**.  **[2011674_20250829HK61800:0]** 
- The company expects to yield **more than $11,500,000** from the PIPE offering and cash released from the trust, after business combination closing-related expenses, to fund future operations.  **[2011674_20250829HK61800:0]** 
- YD Bio Ltd. is a biotechnology company focused on advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, with core programs including blood-based cancer detection, stem cell- and exosome-based ophthalmology therapies, and clinical trial and ancillary services.  **[2011674_20250829HK61800:0]** 
- Dr. Ethan Shen, Chairman of the Board and Chief Executive Officer, stated that becoming a publicly traded Nasdaq-listed company enables the company to accelerate its mission of delivering innovative solutions.  **[2011674_20250829HK61800:1]**

YD Bio (YDES)